logo
PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

Yahoo10-03-2025

BOSTON, March 10, 2025--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the Company will be presenting two oral presentations as well as five posters at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, being held March 16-19, 2025 in Dallas, TX. The oral presentations feature data from the ongoing CONNECT1-EDO51 clinical trial in Duchenne muscular dystrophy (DMD) and from the ongoing FREEDOM-DM1 clinical trial in myotonic dystrophy type 1 (DM1), which the Company recently announced.
Oral Presentations
Title: CONNECT1-EDO51: A 12-Week Open-Label Phase 2 Study to Evaluate PGN-EDO51 Safety and Efficacy in People with Duchenne Amenable to Exon 51 SkippingSession: Clinical Trial UpdatesDate & Time: Wednesday, March 19th at 8:45-9:00 a.m. CTPresenter: Paul Streck, MD, MBA, Executive Vice President, R&D
Title: FREEDOM-DM1: A Phase 1, Placebo-Controlled Single Ascending Dose Study to Evaluate PGN-EDODM1 in People with Myotonic Dystrophy Type 1 (DM1)Session: Clinical Trial UpdatesDate & Time: Wednesday, March 19th at 12:45-1:00 p.m. CTPresenter: Jane Larkindale, DPhil, Vice President, Clinical Science
Poster Presentations
Posters will be displayed beginning at 6:00-8:00 p.m. CT on Sunday, March 16th through Tuesday, March 18th in the conference exhibit hall.
Title: Mechanistic Characterization of Enhanced Delivery Oligonucleotide (EDO) PlatformPoster Number: #P21Presenter: Jane Larkindale, DPhil, Vice President, Clinical Science
Title: Nonclinical Data for PGN-EDODM1 Demonstrated Mechanistic and Meaningful Activity for the Potential Treatment of DM1Poster Number: #P48Presenter: Ashling Holland, PhD, Director, Research & Preclinical Development
Title: Single- and Repeat-Dose Nonclinical Data for PGN-EDO51 Demonstrated Favorable Pharmacology and Safety Profiles for the Treatment of DMDPoster Number: #P49Presenter: Ashling Holland, PhD, Director, Research & Preclinical Development
Title: FREEDOM-DM1: A Phase 1, Placebo-Controlled Single Ascending Dose Study to Evaluate PGN-EDODM1 in People with Myotonic Dystrophy Type 1 (DM1)Poster Number: #O45Presenter: Jennifer Shoskes, PharmD, Associate Director, Clinical Development
Title: CONNECT1-EDO51: A 12-Week Open-Label Phase 2 Study to Evaluate PGN-EDO51 Safety and Efficacy in People with Duchenne Amenable to Exon 51 SkippingPoster Number: #O74Presenter: Bassem Morcos, MD, Medical Director, Clinical Development
Following the conference, the presentations presented at the MDA Clinical & Scientific Conference will be available on the Investors page of PepGen's website under Scientific Publications.
About PGN-EDODM1
PGN-EDODM1, PepGen's investigational candidate in development for the treatment of DM1, utilizes the Company's proprietary EDO technology to deliver a therapeutic oligonucleotide that is designed to restore the normal splicing function of MBNL1, a key RNA splicing protein. PGN-EDODM1 is designed to directly address the deleterious effects of cytosine-uracil-guanine (CUG) repeat expansion in the DMPK transcripts which sequester MBNL1, by binding to the pathogenic CUG trinucleotide repeat expansion present in the DMPK transcripts, disrupting the binding between the CUG repeat expansion and MBNL1. We believe this mechanism will allow the DMPK transcripts to continue performing its normal function within the cell, while also liberating MBNL1 to correct downstream mis-splicing events. We believe that this innovative therapeutic approach has considerable advantages over oligonucleotide modalities that rely on knockdown or degradation of the DMPK transcripts. The FDA has granted PGN-EDODM1 both Orphan Drug and Fast Track Designations for the treatment of patients with DM1.
About PGN-EDO51
PGN-EDO51, PepGen's investigational candidate in development for the treatment of DMD, utilizes the Company's proprietary EDO technology to deliver a therapeutic oligonucleotide that is designed to target the root cause of this devastating disease. PGN-EDO51 is designed to skip exon 51 of the dystrophin transcript, an established therapeutic target for approximately 13% of DMD patients, thereby aiming to restore the open reading frame and enabling the production of a truncated, yet functional dystrophin protein. The FDA has granted PGN-EDO51 both Orphan Drug and Rare Pediatric Disease Designations for the treatment of patients with DMD amenable to an exon-51 skipping approach.
About PepGen
PepGen is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen's EDO platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases.
For more information, please visit PepGen.com. Follow PepGen on LinkedIn and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250310990282/en/
Contacts
Investor Dave Borah, CFASVP, Investor Relations and Corporate Communicationsdborah@pepgen.com
Media Julia DeutschLyra Strategic AdvisoryJdeutsch@lyraadvisory.com

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Musk-Trump Space Showdown Sends Rocket Lab Shares Soaring
Musk-Trump Space Showdown Sends Rocket Lab Shares Soaring

Yahoo

time14 minutes ago

  • Yahoo

Musk-Trump Space Showdown Sends Rocket Lab Shares Soaring

June 9 - Rocket Lab USA Inc (NASDAQ:RKLB) shares climbed about 8% on Monday as investors reacted to a weekend spat between SpaceX CEO Elon Musk and former President Donald Trump. The feud began when Musk criticized Trump's proposed tax legislation on X, prompting Trump to suggest cutting Musk's government contracts. Musk fired back, hinting he might decommission SpaceX's Dragon spacecraft, currently the only U.S. vehicle for ferrying astronauts to the International Space Station, before retracting the comment. Over the weekend, Musk posted that we have got the spaceships, and they do not, implying U.S. reliance on SpaceX. That argument appears to be fueling interest in rival aerospace firms. RKLB, which holds multiple NASA contracts and is viewed as a contender for Trump's $175 billion Golden Dome missile defense initiative, saw its stock hit $31.21 in morning trading. AST SpaceMobile Inc (NASDAQ:ASTS) shares surged about 17% after reports suggested U.S. policymakers may look beyond SpaceX for various space investments. ASTS, a top customer of Blue Origin, inked a November launch deal with Jeff Bezos' company to deploy up to 45 satellites. Both RKLB and ASTS traded on above-average volume, signaling heightened investor focus on alternative space players amid the high-profile Musk-Trump clash. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Are Companies About to Dump Their Bitcoin? The Warning Signs Are Here
Are Companies About to Dump Their Bitcoin? The Warning Signs Are Here

Yahoo

time16 minutes ago

  • Yahoo

Are Companies About to Dump Their Bitcoin? The Warning Signs Are Here

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. The cryptocurrency landscape has witnessed a significant shift as corporations increasingly adopt bitcoin as a treasury asset. While this trend has contributed to bitcoin's recent price surge, it may also be creating new vulnerabilities in the market that warrant careful consideration. Corporate adoption of bitcoin has accelerated notably, with companies following the playbook pioneered by MicroStrategy (NASDAQ:MSTR). According to Bitcoin Treasuries data, 110 publicly listed companies globally now hold bitcoin, representing a substantial institutional commitment to the digital asset. Don't Miss: — no wallets, just price speculation and free paper trading to practice different strategies. Grow your IRA or 401(k) with Crypto – . Standard Chartered's analysis focuses on a refined sample of 61 companies that purchase bitcoin purely as a treasury holding, excluding industry participants like miners, exchanges, and service providers. This subset collectively owned nearly 674,000 bitcoins as of May's end—representing 3.2% of bitcoin's total 21 million coin supply. The numbers tell a compelling story: these 'bitcoin treasuries' have doubled their holdings over just two months, accumulating close to 100,000 additional bitcoins during this period. This buying pressure has been a key factor driving bitcoin to recent all-time highs. However, Standard Chartered's analysis reveals a concerning dynamic that could eventually reverse this supportive trend. Unlike Strategy, which accumulated bitcoin over time at various price points, many newer corporate entrants have purchased at significantly higher average prices. The bank's research suggests that approximately half of the monitored corporate treasuries would find themselves underwater if bitcoin fell below $90,000. This creates a potential domino effect where companies that entered the bitcoin treasury strategy during price peaks could become forced sellers during market downturns. The risk stems from several interconnected factors: Purchase Price Disparities: Most corporate treasuries in Standard Chartered's sample have average purchase prices well above Strategy's cost basis, making them more vulnerable to market volatility. NAV Multiple Justification: Currently, companies holding bitcoin trade at Net Asset Value multiples above 1, justified by market inefficiencies such as regulatory constraints and conservative institutional investment processes. As these barriers diminish over time, the premium valuations may compress. Corporate Pain Thresholds: Unlike dedicated cryptocurrency companies, traditional corporations may have lower tolerance for significant losses on treasury holdings. Standard Chartered estimates that newer entrants likely couldn't withstand a 50% decline from their average purchase price—a threshold that Strategy weathered during the 2022 crypto winter. Trending: New to crypto? on Coinbase. The analysis suggests that if bitcoin drops more than 22% below companies' average purchase prices, forced selling could emerge. This creates a feedback loop where price declines trigger corporate selling, potentially accelerating further declines. This dynamic differs markedly from Strategy's experience in November 2022, when bitcoin halved but the company maintained its position. Several factors may have aided Strategy's resilience: smaller absolute dollar losses at the time, the absence of U.S. spot bitcoin ETFs providing alternative exposure, and the company's fundamental commitment to bitcoin as a long-term strategy. This corporate treasury trend presents both opportunities and risks for the broader bitcoin market: Positive Factors: Corporate adoption provides institutional legitimacy and substantial buying pressure that has supported recent price appreciation. Risk Factors: The concentration of recent purchases at higher price levels creates potential selling pressure during market stress, possibly amplifying volatility. Timing Considerations: As market inefficiencies that currently justify premium valuations are resolved, bitcoin treasuries could shift from price supporters to sources of downside pressure. While corporate bitcoin adoption represents a significant maturation of the cryptocurrency market, investors should recognize that these treasury strategies may behave differently than those of dedicated bitcoin companies during market stress. The sustainability of this trend will likely depend on bitcoin's price stability and these companies' ability to maintain their positions through potential volatility. As Standard Chartered notes, the question isn't whether these companies will face pressure, but rather how much volatility they can withstand before strategic considerations shift. For market participants, understanding these dynamics becomes crucial as corporate treasuries represent an increasingly significant portion of bitcoin's circulating supply. Their behavior during the next major market downturn will provide important insights into the resilience of this newer form of institutional bitcoin adoption. Read Next: A must-have for all crypto enthusiasts: . Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Image: Shutterstock This article Are Companies About to Dump Their Bitcoin? The Warning Signs Are Here originally appeared on

Sharps Technology CEO, Robert Hayes, to Present at the Virtual Investor Summit on June 10, 2025
Sharps Technology CEO, Robert Hayes, to Present at the Virtual Investor Summit on June 10, 2025

Yahoo

time18 minutes ago

  • Yahoo

Sharps Technology CEO, Robert Hayes, to Present at the Virtual Investor Summit on June 10, 2025

Presentation to be webcast live at 10:00 AM ET NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (Nasdaq: 'STSS' and 'STSSW') ('Sharps'), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart safety syringe products to the healthcare industry, today announced that Robert Hayes, CEO, will present at the Virtual Investor Summit on June 10, 2025, at 10:00 AM ET. Investors are invited to listen to the presentation and can register here. Sharps recently announced that the Company has commenced shipments under three customer orders tied to previously announced purchase agreements. These shipments represent the Company's first commercial deliveries and its transition to revenue-generating operations. All products are being manufactured and shipped from Sharps' facility in Hungary, which has undergone significant upgrades to support high-volume production. Read the update release HERE. Presentation Details: Event: Q2 Investor Summit Date & Time: 10:00 AM ET on June 10, 2025 Presenter: Robert Hayes, CEO Webcast: LINK HERE Conference Overview and Structure:The Investor Summit is an exclusive event tailored for investors focused on small- and micro-cap stocks. It offers a unique opportunity to meet with management teams from high-potential emerging companies, gain insights from industry experts, and understand how peers are navigating the current market environment. This quarter's event centers on micro-cap companies that are currently undervalued and positioned near catalyst events that could significantly accelerate their growth trajectory. Registration for Investors:To request free registration, please go to the Investor Summit website, ( and click the "Registration" button. For More Information, please visit: or, contact johnna-mae@ About Sharps Technology:Sharps Technology is an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry. The Company's product lines focus on providing ultra-low waste capabilities, that incorporate syringe technologies that use both passive and active safety features. Sharps also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. The Company has a manufacturing facility in Hungary. For additional information, please visit FORWARD-LOOKING STATEMENTS:This press release contains 'forward-looking statements'. Forward-looking statements reflect our current view about future events. When used in this press release, the words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'future,' 'intend,' 'plan,' 'poised' or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity, and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance, or achievements. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Investor Contact:Holdsworth PartnersAdam HoldsworthPhone: 917-497-9287Email: IR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store